JonesResearch analyst Justin Walsh initiated coverage of Perspective Therapeutics with a Buy rating and $1.40 price target. The firm sees room for Pb-212 TAT whether or not it can improve upon Ac-225 TAT. However, Jones does not believe there is sufficient data to determine the full clinical and/or commercial impact of the issues raised around Ac-225.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on CATX:
- Perspective Therapeutics Reports Third Quarter Fiscal 2023 Results and Recent Business Highlights
- Perspective announces first patient dosed in Phase 1/2a study of VMT-a-NET
- Perspective completes recruitment for first patient cohort in VMT01 trial
- Perspective Therapeutics Completes Recruitment for First Patient Cohort in Phase 1/2a Dose Escalation Trial of VMT01 in Malignant Melanoma
- Perspective Therapeutics’ VMT-a-NET protocols presented at NANETS sympsium